Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Cited by (1,021)

Items 701–800 of 1,021

1. Acquisition and Processing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Specimens in the Era of Targeted Lung Cancer Chemotherapy
   William A. Bulman, Anjali Saqi, Charles A. Powell · 2011 · American Journal of Respiratory and Critical Care Medicine
2. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
   Viola Weijia Zhu, Samuel Jacob Klempner, Sai‐Hong Ignatius Ou · 2019 · Trends in cancer
3. Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma
   Chiara Baldovini, Giulio Rossi, Alessia Ciarrocchi · 2019 · Lung Cancer Targets and Therapy
4. Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
   Xiaozhen Liu, Tao Jiang, Xuefei Li, Chao Zhao, Jiayu Li, Fei Zhou, Limin Zhang, Sha Zhao, Yijun Jia, Jinpeng Shi et al. · 2020 · Journal of Cellular and Molecular Medicine
5. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement
   Molly M. Morgan, Brian P. Johnson, Megan K. Livingston, Linda A. Schuler, Elaine T. Alarid, Kyung Eun Sung, David J. Beebe · 2016 · Pharmacology & Therapeutics
6. Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
   Antonio Passaro, Elena Guerini‐Rocco, Alessia Pochesci, Davide Vacirca, Gianluca Spitaleri, Chiara Catania, Alessandra Rappa, Massimo C.P. Barberis, Filippo de Marinis · 2017 · Pharmacological Research
7. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
   Tri Le, David E. Gerber · 2019 · Cancers
8. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma
   Maity, Tapan K., Venugopalan, Abhilash, Linnoila, Ilona, Cultraro, Constance M., Giannakou, Andreas, Nemati, Roxanne, Zhang, Xu, Webster, Joshua D., Ritt, Daniel, Ghosal, Sarani et al. · 2015 · Cancer Discovery
9. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
   Takayuki Takahama, Kazuko Sakai, Masayuki Takeda, Koichi Azuma, Toyoaki Hida, Masataka Hirabayashi, Tetsuya Oguri, Hiroshi Tanaka, Noriyuki Ebi, Toshiyuki Sawa et al. · 2016 · Oncotarget
10. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
    Meng Li, Jingyu Yang, Wenlong Zhou, Yong Ren, Xiaoxuan Wang, Huiping Chen, Jingyuan Zhang, Junli Chen, Yuhong Sun, Lijuan Cui et al. · 2017 · British Journal of Cancer
11. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
    Jessica J. Lin, Adam Langenbucher, Pranav Gupta, Satoshi Yoda, Isobel J. Fetter, Marguerite M. Rooney, Andrew Do, Marina Kem, Kylie Prutisto-Chang, Audris Oh et al. · 2020 · npj Precision Oncology
12. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study
    Ping Peng, Juejun Gong, Yujie Zhang, Shuchang Zhou, Yichen Li, Guang Han, Rui Meng, Yongshun Chen, Ming Yang, Qian Shen et al. · 2023 · Radiotherapy and Oncology
13. Advances on EGFR mutation for lung cancer.
    Giulio Metro, Lucio Crinò · 2012 · Europe PMC (PubMed Central)
14. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
    Wonjun Ji, Chang‐Min Choi, Jin Kyung Rho, Se Jin Jang, Young Soo Park, Sung‐Min Chun, Woo Sung Kim, Jung‐Shin Lee, Sang‐We Kim, Dae Ho Lee et al. · 2013 · BMC Cancer
15. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group
    Claudia Vollbrecht, Robert Werner, Robert F. H. Walter, Daniel Christian Christoph, Lukas Carl Heukamp, Martin Peifer, Burkhard Hirsch, Lina Burbat, Thomas Mairinger, Kurt Werner Schmid et al. · 2015 · British Journal of Cancer
16. The safety and efficacy of osimertinib for the treatment ofEGFRT790M mutation positive non-small-cell lung cancer
    Xin Yuan Gao, Xiuning Le, Daniel Botelho Costa · 2016 · Expert Review of Anticancer Therapy
17. Drug-biomarker co-development in oncology – 20 years and counting
    Julianne D. Twomey, Nina N. Brahme, Baolin Zhang · 2017 · Drug Resistance Updates
18. MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
    Kristine Raaby Jakobsen, Christina Demuth, Anne Tranberg Madsen, Dianna Hussmann, Johan Vad‐Nielsen, Anders Lade Nielsen, Boe Sandahl Sørensen · 2017 · Oncogenesis
19. Adaptive stress signaling in targeted cancer therapy resistance
    Evangelos Pazarentzos, Trever Grant Bivona · 2015 · Oncogene
20. Molecular model for neuroendocrine prostate cancer progression
    Ruiqi Chen, Xuesen Dong, Martin Edwin Gleave · 2018 · British Journal of Urology
21. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
    Jin‐Ji Yang, Jian Fang, Yongqian Shu, Jianhua Chang, Gongyan Chen, Jian Xing He, Wěi Li, Xiaoqing Liu, Nong Yang, Caicun Zhou et al. · 2020 · Investigational New Drugs
22. A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L)
    Hiroyuki Yamaguchi, Kazushige Wakuda, Minoru Fukuda, Hirotsugu Kenmotsu, Hiroshi Mukae, Kentaro Ito, Kenji Chibana, Kohji Inoue, Satoru Miura, Kentaro Tanaka et al. · 2021 · Journal of Thoracic Oncology
23. Cancer‐associated fibroblasts in nonsmall cell lung cancer: From molecular mechanisms to clinical implications
    Kit-Yee Wong, A. Cheung, Bo-Nan Chen, Wai-Nok Chan, Jun Yu, Kwok-Wai Lo, Wei Kang, Ka-Fai To · 2022 · International Journal of Cancer
24. Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
    Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang · 2022 · Oncology Letters
25. Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
    Kenta Kawasaki, Natasha Rekhtman, Àlvaro Quintanal-Villalonga, Charles M. Rudin · 2022 · Nature Reviews Clinical Oncology
26. Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors
    Rita Dorantes-Heredia, José Manuel Ruiz-Morales, Fernando Cano-García · 2016 · Translational Lung Cancer Research
27. MET/HGF pathway activation as a paradigm of resistance to targeted therapies
    Brian Ko, Tianfang He, Shirish M. Gadgeel, Balázs Halmos · 2017 · Annals of Translational Medicine
28. Axl inhibitors as novel cancer therapeutic agents
    Yingying Shen, Xiguang Chen, Jun He, Duan‐Fang Liao, Xuyu Zu · 2018 · Life Sciences
29. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
    Hiroki Sato, Hiromasa Yamamoto, Masakiyo Sakaguchi, Kazuhiko Shien, Shuta Tomida, Tadahiko Shien, Hirokuni Ikeda, Minami Hatono, Hidejiro Torigoe, Kei Namba et al. · 2018 · Cancer Science
30. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib
    Shingo Miyamoto, Soichiro Ikushima, Ryu Ono, Nobuyasu Awano, Keisuke Kondo, Yoshiaki Furuhata, Kento J. Fukumoto, Toshio Kumasaka · 2015 · Japanese Journal of Clinical Oncology
31. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells
    Isao Kobayashi, Fumiyuki Takahashi, Fariz Nurwidya, Takeshi Nara, Muneaki Hashimoto, Akiko Murakami, Shigehiro Yagishita, Ken Tajima, Moulid Hidayat, Naoko Shimada et al. · 2016 · Biochemical and Biophysical Research Communications
32. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer
    Mong‐Wei Lin, Kang‐Yi Su, Te-Jen Su, Chia‐Ching Chang, Jingwei Lin, Yi‐Hsuan Lee, Sung‐Liang Yu, Jin‐Shing Chen, Min‐Shu Hsieh · 2018 · Lung Cancer
33. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells
    Jun Wang, Oliver R. Mikse, Rachel G. Liao, Yvonne Y. Li, Li Tan, Pasi Antero Janne, Nathanael S. Gray, Kwok‐Kin Wong, Peter S. Hammerman · 2014 · Oncogene
34. Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?
    Mónica Arnedos, Jean‐Charles Soria, Fabrice André, Thomas Tursz · 2014 · Cancer Treatment Reviews
35. TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance
    Xiao-ming Jiang, Yu-Lian Xu, Luo-wei Yuan, Lele Zhang, Mu-yang Huang, Zi-han Ye, Min‐Xia Su, Xiu-ping Chen, Hong‐Jian Zhu, Richard D. Ye et al. · 2020 · Acta Pharmacologica Sinica
36. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
    Alessandra Ferro, G.M. Marinato, Cristiana Mulargiu, Monica Marino, Giulia Pasello, Valentina Guarneri, Laura Bonanno · 2024 · Critical Reviews in Oncology/Hematology
37. Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
    Kazutoshi Isobe, Yoshinobu Hata, Naobumi Tochigi, Kyohei Kaburaki, Hiroshi Kobayashi, Takashi Makino, Hajime Otsuka, Fumitomo Sato, Fumiaki Ishida, Naoshi Kikuchi et al. · 2014 · Journal of Thoracic Oncology
38. Personalized Targeted Therapy for Lung Cancer
    Kehua Wu, Larry K. House, Wanqing Liu, William C.S. Cho · 2012 · International Journal of Molecular Sciences
39. Lineage factors and differentiation states in lung cancer progression
    William K.C. Cheung, Don X. Nguyen · 2015 · Oncogene
40. Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation
    Jamie M. Sperger, Lindsay Nicole Strotman, Allison W. Welsh, Benjamin Pun Casavant, Zachery Chalmers, Sacha Horn, Erika Héninger, Stephanie Margaret Thiede, Jacob J. Tokar, Benjamin K. Gibbs et al. · 2016 · Clinical Cancer Research
41. In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
    Robert Tjin Tham Sjin, Kwangho Lee, Annette O. Walter, Aleksandr Dubrovskiy, Michael P. Sheets, Thia St Martin, Matthew Labenski, Zhendong Zhu, Richland W. Tester, Russell Karp et al. · 2014 · Molecular Cancer Therapeutics
42. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
    Inger Johanne Zwicky Eide, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicėnas, Jussi Pekka Koivunen, Bjørn Henning Grønberg, Odd Terje Brustugun · 2020 · Lung Cancer
43. Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study
    Maximilian Johannes Hochmair, Alessandro Morabito, Desirée Hao, Cheng‐Ta Yang, Ross Andrew Soo, James Chih‐Hsin Yang, Rasim A. Gucalp, Balázs Halmos, Angela Märten, Tanja Čufer · 2020 · Future Oncology
44. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
    Tereza Vaclová, Ursula Grazini, Lewis S. C. Ward, Daniel J. O’Neill, Aleksandra A. Markovets, Xiangning Huang, Juliann Chmielecki, Ryan James Hartmaier, Kenneth Stephen Thress, Paul D. Smith et al. · 2021 · Nature Communications
45. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma
    Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Marc Peeters, Jan Baptist Vermorken, Filip Lardon, An Wouters · 2021 · Medicinal Research Reviews
46. Depression accelerates gastric cancer invasion and metastasis by inducing a neuroendocrine phenotype via the catecholamine/β 2 ‐AR/MACC1 axis
    Changqie Pan, Jianhua Wu, Siting Zheng, Huiying Sun, Yisheng V. Fang, Zhenhua Huang, Min Shi, Liang Li, Jianping Bin, Yulin Liao et al. · 2021 · 癌症：英文版
47. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing
    J-M Sun, Y-L Choi, Jun Ho Ji, Jin Seok Ahn, K.-M. Kim, J. Han, M-J. Ahn, K. Park · 2014 · Annals of Oncology
48. Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
    Josephine Kam Tai Dermawan, Katerina V. Gurova, John J. Pink, Afshin Dowlati, Sarmishtha De, Goutham Narla, Neelesh Sharma, George Robert Stark · 2014 · Molecular Cancer Therapeutics
49. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
    Vera Hirsh · 2015 · BioDrugs
50. Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities
    Nicola Normanno, Anna Maria Rachiglio, Cristin Roma, Francesca Fenizia, Claudia Esposito, Raffaella Pasquale, Maria Libera La Porta, Alessia Iannaccone, Filippo Micheli, Michele L Santangelo et al. · 2012 · Journal of Cellular Biochemistry
51. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients
    Akira Inoue, Kazushi Yoshida, Satoshi Morita, Fumio Imamura, Takashi Seto, Isamu Okamoto, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Satoshi Muto, Masahiro Fukuoka · 2016 · Japanese Journal of Clinical Oncology
52. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
    Bjoern Titz, Anastasia Lomova, Allison Le, Willy Hugo, Xiangju Kong, Johanna ten Hoeve, Michael Friedman, Hubing Shi, Gatien Moriceau, Chunying Song et al. · 2016 · Cell Discovery
53. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation
    Meredith K Bollinger, Amanda S Agnew, Gerard P. Mascara · 2017 · Journal of Oncology Pharmacy Practice
54. Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1
    Yuhong Lü, Yanfeng Liu, Sebastian Oeck, Peter M. Glazer · 2018 · Molecular Cancer Research
55. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
    Yuxin Mu, Xuezhi Hao, Puyuan Xing, Xingsheng Hu, Yan Wang, Teng Li, Jinyao Zhang, Ziyi Xu, Junling Li · 2020 · Journal of Cancer Research and Clinical Oncology
56. Less Is More: Rare Pulmonary Neuroendocrine Cells Function as Critical Sensors in Lung
    Jinhao Xu, Haoze Vincent Yu, Xin Sun · 2020 · Developmental Cell
57. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Arjan Gower, Yisong Wang, Giuseppe Giaccone · 2014 · Journal of Molecular Medicine
58. Ligand‐triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands
    Seiji Yano, Shinji Takeuchi, Takayuki Nakagawa, Tadaaki Yamada · 2012 · Cancer Science
59. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
    Maricla Galetti, Pier Giorgio Petronini, Claudia Fumarola, Daniele Cretella, Silvia La Monica, Mara A. Bonelli, Andrea Cavazzoni, Francesca Saccani, Cristina Caffarra, Roberta Andreoli et al. · 2015 · PLoS ONE
60. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC
    Ahn, Myung-Ju, Lisberg, Aaron, Goto, Yasushi, Sands, Jacob, Hong, Min Hee, Paz-Ares, Luis, Pons-Tostivint, Elvire, Pérol, Maurice, Felip, Enriqueta, Sugawara, Shunichi et al. · 2025 · Journal of Thoracic Oncology
61. Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.
    Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo · 2015 · PubMed Central
62. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study
    Naoko Sueoka‐Aragane, Nobuyuki Katakami, Miyako Satouchi, Soichiro Yokota, Keisuke Aoe, Kentaro Iwanaga, Kojiro Otsuka, Satoshi Morita, Shinya H Kimura, Shunichi Negoro et al. · 2015 · Cancer Science
63. DeSigN: connecting gene expression with therapeutics for drug repurposing and development
    Bernard Kok Bang Lee, Kai Hung Tiong, Jit Kang Chang, Chee Sun Liew, Zainal Ariff Abdul Rahman, Aik Choon Tan, Tsung Fei Khang, Sok Ching Cheong · 2017 · BMC Genomics
64. Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts
    Yung‐Jue Bang, Wu‐Chou Su, Martin Schüler, Do‐Hyun Nam, Wan Teck Lim, Todd Michael Bauer, Analía Azaro, Ronnie T. P. Poon, David S. Hong, Chia‐Chi Lin et al. · 2019 · Cancer Science
65. High-throughput functional evaluation of human cancer-associated mutations using base editors
    Younggwang Kim, Seung‐Ho Lee, Soohyuk Cho, Jinman Park, Dongwoo Chae, Taeyoung Park, John Dorrance Minna, Seokjoong Kim · 2022 · Nature Biotechnology
66. Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition
    Pavel A. Levin, Melissa Mayer, Sharon Hoskin, Joseph L. Sailors, Dwight Oliver, David E. Gerber · 2015 · Journal of Thoracic Oncology
67. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
    Daniele Cretella, Francesca Saccani, Federico Quaini, Caterina Frati, Costanza Annamaria Lagrasta, Mara A. Bonelli, Cristina Caffarra, Andrea Cavazzoni, Claudia Fumarola, Maricla Galetti et al. · 2014 · Molecular Cancer
68. AXL is an oncotarget in human colorectal cancer
    Erika Martinelli, Giulia Martini, Claudia Cardone, Teresa Troiani, Giuseppina Liguori, Donata Vitagliano, Stefania Napolitano, Floriana Morgillo, Barbara Rinaldi, Rosa Marina Melillo et al. · 2015 · Oncotarget
69. Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA 3 trial
    Hiroaki Akamatsu, Nobuyuki Katakami, Isamu Okamoto, Terufumi Kato, Young Hak Kim, Fumio Imamura, Masaharu Shinkai, Rachel A. Hodge, Hirohiko Uchida, Toyoaki Hida · 2018 · Cancer Science
70. High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing
    Xiaojun Yan, Lyu Zhou, Zhaozhao Wu, Xun Wang, Xiuyuan Chen, Fan Yang, Yanan Guo, Min Wu, Yuyang Chen, Wenjing Li et al. · 2018 · Biomaterials
71. The Evolving Landscape of Resistance to Osimertinib
    Adam Jacob Schoenfeld, Helena Alexandra Yu · 2019 · Journal of Thoracic Oncology
72. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
    Michihiko Kuwano, Kahori Sonoda, Yûichi Murakami, Kosuke Watari, Mayumi Ono · 2016 · Pharmacology & Therapeutics
73. The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer
    Wen‐Zhao Zhong, Qing Hua Zhou, Yi-Long Lung Cancer Wu · 2017 · Oncotarget
74. TGIF2 promotes the progression of lung adenocarcinoma by bridging EGFR/RAS/ERK signaling to cancer cell stemness
    Renle Du, Wenzhi Shen, Yi Liu, Wenjuan Gao, Wei Zhou, Jun Li, Shuangtao Zhao, Chong Chen, Yanan Chen, Yanhua Liu et al. · 2019 · Signal Transduction and Targeted Therapy
75. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403
    Sarah B. Goldberg, Mary Weber Redman, Rogério Lilenbaum, Katerina A. Politi, Thomas E. Stinchcombe, Leora Horn, Everett H. Chen, Sandeep H. Mashru, Scott N. Gettinger, Mary Ann Melnick et al. · 2020 · Journal of Clinical Oncology
76. The role of epithelial plasticity in prostate cancer dissemination and treatment resistance
    Rhonda Lynn Bitting, Daneen Schaeffer, Jason A. Somarelli, Mariano A. García-Blanco, Andrew J. Armstrong · 2014 · Cancer and Metastasis Reviews
77. Personalized Therapy for Lung Cancer
    Andre Luis Moreira, Juliana Eng · 2014 · CHEST Journal
78. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
    Ivana Sullivan, David Planchard · 2016 · Therapeutic Advances in Respiratory Disease
79. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
    Marı́a Eugenia Riveiro, Lucile Astorgues‐Xerri, Ramiro Vázquez, Roberta Frapolli, Ivo Kwee, Andrea Rinaldi, Elodie Odore, Keyvan Rezaï, Mohamed Békradda, Giorgio Inghirami et al. · 2016 · Oncotarget
80. Role of long non‐coding RNA in drug resistance in non‐small cell lung cancer
    Leirong Wang, Leina Ma, Fei Xu, Wenxin Zhai, Shenghua Dong, Ling Yin, Jia Liu, Zhuang Yu · 2018 · Thoracic Cancer
81. Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer
    Yunkyoung Lee, Sojung Park, Woo Sung Kim, Jae Cheol Lee, Se Jin Jang, Jene Choi, Chang‐Min Choi · 2018 · Thoracic Cancer
82. Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
    Satoshi Yoda, Ibiayi Dagogo‐Jack, Aaron N. Hata · 2018 · Pharmacology & Therapeutics
83. Will liquid biopsies improve outcomes for patients with small-cell lung cancer?
    Fiona Helen Blackhall, Kristopher K. Frese, Kathryn Simpson, Elaine Kilgour, Gerard Brady, Caroline Dive · 2018 · The Lancet Oncology
84. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer
    Jair Bar, Efrat Ofek, Iris Barshack, Teodor Gottfried, Oranit Zadok, Iris Kamer, Damien Urban, Marina Perelman, Amir Onn · 2019 · Lung Cancer
85. Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options
    Joseph Burnett, Hasan Körkaya, Maria Ouzounova, Hui Jiang, Sarah J. Conley, Bryan W. Newman, Lichao Sun, Jamie N. Connarn, Ching‐Shih Chen, Ning Zhang et al. · 2015 · Scientific Reports
86. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients
    Sai‐Hong Ignatius Ou, Leora Horn, Marcelo Rocha Cruz, Davood Vafai, Christine Marie Lovly, Allison Spradlin, Michael J. Williamson, Ibiayi Dagogo‐Jack, Adrienne Johnson, Vincent A. Miller et al. · 2017 · Lung Cancer
87. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
    Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong‐Soo Park, Yeon‐Sun Seong · 2021 · Pharmaceuticals
88. Targeted Anti-Mitochondrial Therapy: The Future of Oncology
    Farzad Taghizadeh‐Hesary, Babak Behnam, Hassan Akbari, Moslem Bahadori · 2022 · Genes
89. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI
    Tony S.K. Mok, Pasi Antero Janne, Makoto Nishio, Silvia Novello, Martin Reck, Conor Ernst Steuer, Yi-Long Wu, Ronan Fougeray, Pang‐Dian Fan, Jie Meng et al. · 2023 · Future Oncology
90. A nanoparticle formulation that selectively transfects metastatic tumors in mice
    Jian Yang, William P.D. Hendricks, Guosheng Liu, J. Michael McCaffery, Kenneth W. Kinzler, David L. Huso, Bert Vogelstein, Shibin Zhou · 2013 · Proceedings of the National Academy of Sciences
91. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
    Niki Karachaliou, Jordi Codony‐Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony, Ana A. Giménez-Capitán, Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, R. Gervais et al. · 2015 · Scientific Reports
92. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
    Kimio Yonesaka, Keita Kudo, Satomi Nishida, Takayuki Takahama, Tsutomu Iwasa, Takeshi Yoshida, Kaoru Tanaka, Masayuki Takeda, Hiroyasu Kaneda, Isamu Okamoto et al. · 2015 · Oncotarget
93. Insight into the Inhibition of Drug‐Resistant Mutants of the Receptor Tyrosine Kinase EGFR
    Julian Engel, Christian Becker, Jonas Lategahn, Marina Keul, Julia Ketzer, Thomas Mühlenberg, Laxmikanth Kollipara, Carsten Schultz‐Fademrecht, René Peiman Zahedi, Sebastian Bauer et al. · 2016 · Angewandte Chemie International Edition
94. Cordycepin Induces Apoptosis and Inhibits Proliferation of Human Lung Cancer Cell Line H1975 via Inhibiting the Phosphorylation of EGFR
    Zheng Wang, Xue Wu, Yan-Ni Liang, Li Wang, Zhongxing Song, Jianli Liu, Zhishu Tang · 2016 · Molecules
95. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
    Chiara Tomasello, Cinzia Baldessari, Martina Napolitano, Giulia Orsi, Giulia Grizzi, Federica Bertolini, Fausto Barbieri, Stefano Cascinu · 2018 · Critical Reviews in Oncology/Hematology
96. Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
    Guillaume Herbreteau, Audrey Vallée, Sandrine Charpentier, Nicola Normanno, Paul M Hofman, Marc Guillaume Denis · 2019 · Journal of Thoracic Disease
97. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
    Anish Thomas, Arun Rajan, Ariel López-Chávez, Y. Wang, Giuseppe Giaccone · 2012 · Annals of Oncology
98. A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer
    Scott N. Gettinger, Thomas James Lynch · 2011 · Clinics in Chest Medicine
99. Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
    Andreas N. WICKI, Mario Mandalà, Daniela Massi, Daniela Taverna, Huifang Tang, Brian A. Hemmings, Gongda Xue · 2016 · Physiological Reviews
100. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
     Sehhoon Park, Joonho Shim, Boram Lee, Inju Cho, Woong‐Yang Park, Youjin Kim, Se‐Hoon Lee, Yoon‐La Choi, Joungho Han, Jin Seok Ahn et al. · 2019 · Lung Cancer